Category - Developments

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Developments

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Rainhouse Manufacturing Canada, a well-established North American CNC machining and manufacturing company, emphasized a recent CNN interview with Dr. Sanjay Gupta, which uncovered the real cause of weight-loss drug...

July 12, 2024

Developments

Remembering Elias Vamvakas, a friend and mentor

For the first time since we began publishing in 2009, the BioTuesdays family is lost for words, almost. With devastating sadness, we learned today of Elias Vamvakas’ passing. A pioneering entrepreneur in the Canadian...

July 11, 2024

Developments

Exscientia launches AWS AI-powered platform to advance drug discovery

Exscientia plc (NASDAQ:EXAI) announced its use of Amazon Web Services (AWS) artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia’s...

July 10, 2024

Developments

Unicycive announces positive topline results from pivotal clinical trial in hyperphosphatemia

Unicycive Therapeutics (NASDAQ:UNCY) announced positive initial results from the patient reported outcome survey conducted during its pivotal clinical trial of oxylanthanum carbonate (OLC) in patients with...

July 10, 2024

Developments

Mainz Biomed submits application for FDA breakthrough device designation for CRC product

Mainz Biomed (NASDAQ:MYNZ) announced that it has submitted an application to the FDA requesting breakthrough device designation for its non-invasive, next-generation colorectal cancer (CRC) screening test, which...

July 9, 2024

Developments

ABVC announces joint effort with AiBtl for new clinical study on depression in cancer patients using AI

ABVC BioPharma (NASDAQ:ABVC) announced plans for a new clinical study in collaboration with AiBtl BioPharma on depression in cancer patients by integrating AI-driven solutions. The new study follows successful Phase II...

July 9, 2024

Developments

Defence announces receipt of NOL for Phase I trial of anti-cancer molecule

Defence Therapeutics (CSE:DTC; OTCQB:DTCFF; FSE:DTC) announced that it has received a “no objection letter” (NOL) from Health Canada authorizing the company to proceed with a Phase I trial of intratumoral administration...

July 8, 2024

Developments

CellProthera and BioCardia announce successful results from collaborative Phase II trial

Closely-held CellProthera, in collaboration with BioCardia (NASDAQ:BCDA), announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI). The companies plan...

July 8, 2024

Category - Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Remembering Elias Vamvakas, a friend and mentor

Exscientia launches AWS AI-powered platform to advance drug discovery

Unicycive announces positive topline results from pivotal clinical trial in hyperphosphatemia

Mainz Biomed submits application for FDA breakthrough device designation for CRC product

ABVC announces joint effort with AiBtl for new clinical study on depression in cancer patients using AI

Defence announces receipt of NOL for Phase I trial of anti-cancer molecule

CellProthera and BioCardia announce successful results from collaborative Phase II trial

General

More